Antithrombotic Therapy for VTE Disease

ACCP VTE Therapy

ACCP GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/86135

Contents of this Issue

Navigation

Page 10 of 17

Pulmonary Embolus Clinical Suspicion High Test results > 4h Intermediate Test results ≤ 24h Low AND VKA x ≥ 5d and INR ≥ 2.0 x > 24h LMWH daily or fondaparinux (or IV or subcut UFH) x ≥ 5d and INR ≥ 2.0 x > 24h If contraindicated IVC filter Anticoagulation if bleed risk resolves 3 months Surgical 1st high bleed risk or 2nd Duration of Anticoagulation by Cause Extended Transient Factor Unprovoked – Unprovoked 1st low-moderate bleed risk Cancer (LMWH preferred) or 2nd Unprovoked – Await test results (SBP ≤ 90 mmHg) Hypotension (2 h infusion via peripheral vein) Thrombolysis • Contraindications to thrombolysis • Failed thrombolysis • Shock – lethal within hours Catheter-assisted thrombus removal OR embolectomy Pulmonary 9

Articles in this issue

Archives of this issue

view archives of Antithrombotic Therapy for VTE Disease - ACCP VTE Therapy